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Abstract
Purpose This study was conducted to determine the
pharmacokinetics of aprepitant and dexamethasone as
well as the relationship between the plasma concentration
of substance P and nausea/vomiting in Japanese cancer
patients.
Methods After administration of aprepitant (125/80 mg
group [10 patients]: 125 mg on day 1 and 80 mg on days
2–5; 40/25 mg group [10 patients]: 40 mg on day 1 and
25 mg on days 2–5) and dexamethasone (6 mg on day 1
and 4 mg on days 2 and 3 in the 125/80 mg group, and
8 mg on day 1 and 6 mg on days 2 and 3 in the 40/25 mg
group) to Japanese cancer patients receiving at least mod-
erately emetogenic antitumor agents, the plasma concen-
trations of aprepitant, dexamethasone, and substance P
were measured.
Results All of 20 patients were treated with the highly
emetogenic agent cisplatin (C70 mg/m
2). The Cmax and
AUC0–24 h of aprepitant in Japanese cancer patients were
similar with those in non-Japanese patients. The clearance
of dexamethasone in the 125/80 mg group was approxi-
mately one-half of that previously determined in the
absence of aprepitant. The substance P concentration in
plasma signiﬁcantly increased only in patients with delayed
nausea/vomiting.
Conclusions This study demonstrated similar plasma
pharmacokinetics of aprepitant in Japanese and non-Japa-
nese, the validity of reducing dexamethasone dose, and
the existence of increased plasma substance P concentra-
tion in patients receiving highly emetogenic cisplatin-based
chemotherapy.
Keywords Aprepitant  Dexamethasone  Substance P 
Pharmacokinetics  Chemotherapy-induced nausea and
vomiting
Introduction
Aprepitant is a neurokinin-1 (NK1) receptor antagonist
developed as a treatment for both acute and delayed che-
motherapy-induced nausea and vomiting (CINV). It has a
novel mechanism of action (i.e., by inhibiting the binding
of substance P to the NK1 receptor in the vomiting center)
[1–3]. In the guidelines for management of CINV, aprep-
itant is recommended to be used in combination with a
serotonin antagonist and dexamethasone to prevent nausea/
vomiting induced by highly and moderately emetogenic
cancer chemotherapy [4–6].
Although aprepitant has no effect on the pharmacoki-
netics of serotonin antagonists (ondansetron, granisetron,
palonosetron) [7, 8], aprepitant inhibits CYP3A4 and in
turn inhibits the metabolism of dexamethasone, a substrate
of CYP3A4 [9]. It has been shown that the area under the
concentration–time curve (AUC) of dexamethasone is
increased approximately two times after administration of
aprepitant at a dose of 125 mg on day 1 and at a dose of
80 mg on days 2–5 in healthy adults, and so, to maintain
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presence of aprepitant, the dose of dexamethasone has to
be reduced by 50% [9]. Although a previous population
pharmacokinetic study of dexamethasone combined with
aprepitant supported the validity of this dose reduction
of dexamethasone [10], there has been no full pharma-
cokinetic study of dexamethasone and aprepitant in
cancer patients who receive emetogenic cancer chemo-
therapy.
While aprepitant may have an antiemetic effect by
inhibiting the binding of substance P to the NK1 receptor in
the vomiting center as mentioned above, it is still unclear
whether there is any change in the in vivo kinetics of
substance P after administration of chemotherapeutic
agents, or how the in vivo kinetics of substance P is related
to CINV.
This study was conducted to determine the pharmaco-
kinetics of aprepitant as well as dexamethasone in Japanese
cancer patients and to verify the dose reduction of dexa-
methasone used in combination with aprepitant, and fur-
thermore, to evaluate the relationship between CINV and in
vivo kinetics of substance P after administration of che-
motherapeutic agents.
Patients and methods
Inclusion criteria
Japanese cancer patients aged between 20 and 74 years
who received cancer chemotherapy were included in this
study. Cancer chemotherapy consisted of at least moder-
ately (Hesketh level C 3[ 11]) emetogenic chemothera-
peutic agents on day 1 only. With a performance status of
0–2 and an estimated life expectancy of at least 3 months,
patients met the following laboratory criteria: white blood
cell count C 3,000/mm
3 and neutrophil count C 1,500/
mm
3; platelet count C 100,000/mm
3; AST (GOT) and
ALT (GPT) B 1.5 9 upper limit of the normal range at the
facility; ALP B 2.5 9 upper limit of the normal range
at the facility; total bilirubin B 1.5 mg/dL; and creati-
nine B 1.5 mg/dL. The following patients were excluded
from the study: patients with a risk of vomiting for other
reasons (symptomatic brain metastasis, meningeal inﬁltra-
tion, epilepsy, active peptic ulcer, gastrointestinal obstruc-
tion, concomitant abdominal or pelvic radiotherapy, etc.);
and pregnant, nursing, or possibly pregnant women. After
the protocol and informed consent form were approved by
the institutional review board (IRB) at the facility, patients
who gave written informed consent were enrolled. All
studies were conducted in accordance with the principles of
Good Clinical Practice (GCP) and the basic principles of the
Declaration of Helsinki.
Design and treatment
This was an open-label study. A total of 20 patients were
randomized to receive aprepitant at an oral dose of 125/
80 mg (125 mg on day 1 and 80 mg on days 2–5; n = 10)
or 40/25 mg (40 mg on day 1 and 25 mg on days 2–5;
n = 10). In addition, all patients received standard antie-
metic therapy consisting of intravenous granisetron (40 lg/
kg on day 1) and intravenous dexamethasone sodium
phosphate (on days 1–3). In this study, the dose of intra-
venous dexamethasone was 6 mg on day 1 and 4 mg on
days 2 and 3 in the 125/80-mg group and 8 mg on day 1
and 6 mg on days 2 and 3 in the 40/25 mg group.
Although, in the antiemetic guidelines [4–6], it is recom-
mended that dexamethasone is administered at a dose of
12 mg on day 1 and at a dose of 8 mg on day 2 and
thereafter in combination with aprepitant 125/80 mg, the
dose of dexamethasone in this study was determined in
order to compare the clearance of dexamethasone in this
study with that obtained from Japanese cancer patients in
the absence of aprepitant at a dose of 12 mg dexametha-
sone on day 1 [10].
Pharmacokinetic evaluation
Blood samples for measurement of plasma aprepitant
concentration were collected before administration of
aprepitant on days 1–5 and 1, 2, 3, 5, 9, 11, and 24 h after
administration of aprepitant on day 1 and on day 5 only. In
addition, a separate set of blood samples for measurement
of plasma dexamethasone concentration were collected
immediately, 15 min, 30 min, and 1.5, 3.5, 7.5, 9.5, and
22.5 h after administration of dexamethasone on day 1.
Methods for measurement of plasma aprepitant
and dexamethasone concentrations
For each subject, venous blood was collected in an EDTA
2Na-treated tube at each sampling time point and imme-
diately centrifuged at approximately 1,500g (approxi-
mately 3,000 rpm) for 10 min at room temperature. Then,
the resultant plasma was transferred to a polypropylene
tube and stored frozen at -20C. The plasma concentra-
tions of aprepitant and dexamethasone were measured by
liquid chromatography/tandem mass spectrometry (LC/
MS/MS). After methanol was added to plasma, the internal
standard and carbonate buffer (for aprepitant) or ammo-
nium acetate buffer (for dexamethasone) were added and
mixed. Then, t-butyl methyl ether (for aprepitant) or die-
thyl ether (for dexamethasone) was added to and mixed
with the plasma sample and centrifuged. After the aqueous
layer was frozen in a methanol/dry ice bath, the entire
organic layer was collected in a tube and placed under
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123nitrogen stream at approximately 40C to remove the sol-
vent. The residue was suspended in ammonium acetate
aqueous solution (containing formic acid)/acetonitrile (for
aprepitant) or methanol/water (for dexamethasone) for use
in LC/MS/MS.
The pharmacokinetic parameters of aprepitant and
dexamethasone were calculated by non-compartment
analysis using WinNonlin Professional
 software Ver.4.0.1
(Pharsight Corporation, Mountain View, CA, USA). The
maximum plasma concentration (Cmax), time to maximum
plasma concentration (tmax), and area under the plasma
concentration–time curve from 0 to 24 h post-dose
(AUC0–24 h) were calculated for aprepitant, and the Cmax,
area under the plasma concentration–time curve from 0 to
inﬁnity (AUC0–?), t1/2, total clearance (CLtot), and volume
of distribution at steady state (Vss) were calculated for
dexamethasone.
Assessment of substance P
Before administration of aprepitant on days 1–5, venous
blood was collected in an ethylenediaminetetraacetic acid
(EDTA)/aprotinin-treated tube from each subject and
inverted to mix. After blood was immediately centrifuged
at 1,500g (approximately 3,000 rpm) for 10 min at 4C,
0.5 mL of plasma was stored frozen at –20C. The plasma
substance P concentration was measured by enzyme
immunoassay (EIA).
Statistical analysis
To assess ethnic differences in the pharmacokinetics of
aprepitant, the Cmax and AUC0–24 h at a dose of 125 mg in
Japanese cancer patients were compared with those in non-
Japanese cancer patients [12] by calculating the geometric
mean ratio (Japanese/non-Japanese) and its 90% conﬁ-
dence interval for each parameter.
To assess the validity of adjusting the dose of dexa-
methasone in the 125/80 and 40/25 mg groups, the expo-
sure levels of dexamethasone were compared. The Cmax
and AUC0–? of dexamethasone in each group were used to
calculate the geometric mean ratio (125/80 mg group/40/
25 mg group) and its 90% conﬁdence interval for each
parameter. In addition, the clearance of dexamethasone in
each group was compared with that calculated in the
absence of aprepitant in Japanese cancer patients [10].
For substance P, the plasma concentration on each
measurement day was used to assess the change on day 2
and thereafter, and these changes were evaluated by paired
t test.
This study was designed and funded by Ono pharma-
ceutical Co., Ltd. and Merck & Co., Inc., the manufacturer
of aprepitant.
Results
Patients
A total of 20 patients (10 in the 125/80 mg group and 10 in
the 40/25 mg group) were included. Patients’ characteris-
tics are shown in Table 1. There were 18, 1, and 1 patients
with non–small cell lung cancer, small-cell lung cancer,
and mesothelioma, respectively. All were treated with at
least the highly emetogenic chemotherapeutic agent cis-
platin (C70 mg/m
2). The two groups were generally sim-
ilar in age, sex, height, and body weight.
Pharmacokinetics of aprepitant
All 20 enrolled patients were included in the pharmacoki-
netic analysis. The pharmacokinetic parameters of aprep-
itant are shown in Table 2. In the 125/80 mg group, the
AUC0–24 h on days 1 and 5 increased out of proportion to
the dose, compared with that in the 40/25 mg group.
The geometric mean ratio and its 90% conﬁdence
interval (CI) of the Cmax and AUC0–24 h of aprepitant in
Japanese cancer patients to non-Japanese cancer patients
was 1.09 (0.79–1.52) and 1.12 (0.87–1.45), respectively,
Table 1 Characteristics of patients
Characteristics 125/80 mg
regimen
n = 10
40/25 mg
regimen
n = 10
Male/female (N) 6/4 7/3
Age (years)
Mean (S.D.) 59.7 (6.7) 63.6 (5.9)
Range 47–71 55–72
Height (cm)
Mean (S.D.) 161.16 (9.91) 161.24 (12.97)
Range 147.0–179.5 139.2–177.3
Weight (kg)
Mean (S.D.) 55.72 (10.28) 56.86 (14.17)
Range 42.2–76.6 42.4–82.7
Primary cancer diagnosis (N)
Non–small cell lung cancer 9 9
Small-cell lung cancer 1 0
Mesothelioma 0 1
Chemotherapy regimen (N)
Cisplatin ? gemcitabine 3 5
Cisplatin ? tegafur/gimeracil/
oteracil
22
Cisplatin ? vinorelbine 2 2
Cisplatin ? etoposide 2 0
Cisplatin ? docetaxel 1 1
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123showing little differences between Japanese and non-
Japanese groups in the pharmacokinetics of aprepitant.
Pharmacokinetics of dexamethasone
For dexamethasone, the pharmacokinetic parameters and
time proﬁle of plasma concentration on day 1 in the 125/80
and 40/25 mg groups are shown in Table 3 and Fig. 1,
respectively. The geometric mean ratio (90% CI) of Cmax
and AUC0–? of dexamethasone on day 1 in the 125/80 mg
group to the 40/25 mg group was 0.83 (0.73–0.94) and 1.15
(0.88–1.50), respectively, showing that although the Cmax
tended to be high in the 40/25 mg group, the AUC0–?was
similar between the two treatment groups. To verify the
dose reduction of dexamethasone in cancer patients who
receive emetogenic cancer chemotherapy in combination
with aprepitant, we compared the clearances of dexa-
methasone in this study with that obtained from Japanese
cancer patients in the absence of aprepitant at a dose of
12 mg on day 1 (13.3 L/h) [10]. In the 125/80 and 40/
25 mg groups (dexamethasone at a dose of 6 and 8 mg on
day 1, respectively), the clearance of dexamethasone was
6.48 and 10.0 L/h, respectively. That is, the clearances of
dexamethasone in the 125/80 and 40/25 mg groups
decrease by approximately 52 and 25%, respectively.
These results demonstrate the validity of reducing the dose
of dexamethasone by 50 and 25% in the 125/80 and 40/
25 mg groups, compared with the dose of dexamethasone
in the absence of aprepitant.
Evaluation of plasma substance P
The time proﬁle of plasma substance P concentration after
administration of chemotherapeutic agents in all 20
patients (days 1–5) is shown in Fig. 2. The substance P
Table 2 Summary of the pharmacokinetics of aprepitant on days 1
and 5
Day Parameter 125/80 mg
regimen
40/25 mg
regimen
1C max (ng/mL) 2,210 ± 870 536 ± 105
Tmax (h) 7.0 (3.0–9.0) 3.0 (2.0–9.0)
AUC0–24 h (ngh/mL) 30,000 ± 8,700 6,360 ± 1,350
5C max (ng/mL) 3,070 ± 850 453 ± 109
Tmax (h) 3.0 (2.0–9.0) 3.0 (2.0–3.0)
AUC0–24 h (ngh/mL) 46,000 ± 17,100 5,420 ± 1,680
Mean ± SD, Tmax median (range)
Cmax, maximum plasma concentration, Tmax, time to maximum
plasma concentration, AUC0–24 h area under plasma concentration–
time curve from 0 to 24 h post-dose
Table 3 Pharmacokinetic parameters of dexamethasone in each
treatment group (on day 1)
Parameter 125/80 mg regimen
(Dexamethasone
6 mg)
40/25 mg regimen
(Dexamethasone
8 mg)
Cmax (ng/mL) 121 ± 17 147 ± 27
AUC0–t (ngh/mL) 823 ± 213 838 ± 253
AUC0–? (ngh/mL) 1,020 ± 300 899 ± 287
t1/2 (h) 9.6 ± 2.4 5.7 ± 1.4
CLtot (L/h) 6.48 ± 2.50 10.0 ± 4.1
Vss (L) 74.6 ± 14.3 65.5 ± 11.7
Mean ± SD
Cmax maximum plasma concentration, AUC0–t, area under plasma
concentration–time curve from 0 to the last measurable concentration,
AUC0–?, area under plasma concentration–time curve from 0 to
inﬁnity, t1/2 elimination half-life, CLtot total clearance, Vss volume of
distribution at steady state
Fig. 1 Time proﬁle of plasma dexamethasone concentration in each
treatment group (day 1). Mean ? SD (n = 10)
Fig. 2 Time proﬁle of plasma substance P concentration (n = 20).
Top bar highest value in the range of quartile 9 1.5; lower bar lowest
value in the range of quartile 9 1.5; top of box upper quartile; bottom
of box lower quartile; middle bar: median value; circles outliers
*P\0.05 compared with baseline (day 1) concentration
656 Cancer Chemother Pharmacol (2011) 68:653–659
123concentration signiﬁcantly increased on days 2–4, com-
pared with that on day 1 (baseline) (P\0.05, paired t test).
There was no difference in the change in the plasma
substance P concentration between the 125/80 and 40/
25 mg groups (data not shown). The change in substance P
concentration in plasma from baseline (the concentration
before the start of treatment with aprepitant) in patients
with or without delayed nausea/vomiting is shown in
Fig. 3. One patient had missing data for the substance P
concentration on day 1, and so we analyzed the change in
substance P concentration from baseline (day 1) in 19
patients. In patients with delayed nausea/vomiting, sub-
stance P concentration increased signiﬁcantly between
days 2 and 5 compared with baseline (day 1) (P\0.05,
paired t test). On the other hand, in patients without
delayed nausea/vomiting, the increase in substance P
concentration on days 2–5 was not statistically signiﬁcant.
Discussion
In this study, the pharmacokinetics of aprepitant and
dexamethasone were determined in Japanese cancer
patients receiving emetogenic chemotherapeutic agents.
There were no differences in the pharmacokinetics of
aprepitant between Japanese and non-Japanese cancer
patients. In addition, we showed the validity of dose
adjustment of dexamethasone used in combination with
aprepitant (i.e., reducing the dose of dexamethasone by
50% when combined with 125 mg of aprepitant). We also
found that the blood concentration of substance P, which is
deeply involved in the pharmacological effects of aprep-
itant, increased after administration of chemotherapeutic
agents.
In the present study, the geometric mean ratio of the
Cmax and AUC0–24 h in Japanese cancer patients to non-
Japanese cancer patients was 1.09 and 1.12, respectively,
indicating no ethnic differences in the pharmacokinetics of
aprepitant. In the aprepitant 125/80 mg group, more than
dose-proportional increase in AUC0–24 h occurred on both
days 1 and 5, compared with that in the 40/25 mg group.
Aprepitant is primarily metabolized by CYP3A4 [13], and
this more than proportional increase in the AUC0–24 h of
aprepitant may reﬂect saturated metabolism of aprepitant
via CYP3A4 as previously reported in healthy non-Japa-
nese volunteers [14].
In this study, granisetron hydrochloride and dexameth-
asone sodium phosphate were concomitantly used as
standard antiemetic therapy. Aprepitant–dexamethasone
interaction causes the increase in plasma dexamethasone
concentration [9], and it has been suggested that this drug
interaction may also cause a slight increase in the incidence
of infection-related serious adverse events [15]. Since the
AUC of dexamethasone (p.o.) has been shown to increase
approximately two times after administration of aprepitant
at a dose of 125 mg on day 1 in healthy adults [9], the dose
of dexamethasone has to be reduced by 50% when used in
combination with 125 mg of aprepitant. While oral dexa-
methasone was used in the report by McCrea et al. [9], this
was the ﬁrst full pharmacokinetic study of intravenous
administration of dexamethasone when used in combina-
tion with aprepitant in cancer patients actually receiving
chemotherapeutic agents. In the 125/80 mg group, the
clearance of intravenous dexamethasone decreased by
approximately 52% from that calculated in the absence of
aprepitant, justifying a 50% dose reduction of intravenous
dexamethasone used in combination with 125 mg of
aprepitant in cancer patients as McCrea et al. demonstrated
in healthy adults [9]. And the results from this full phar-
macokinetic study also supported a report using a popula-
tion pharmacokinetics model by Nakade et al. [10] that the
clearance of intravenous dexamethasone used in combi-
nation with aprepitant at a dose of 125 mg decreased by
47.5% of that in the absence of aprepitant.
While aprepitant may exert its antiemetic effect during
chemotherapy, by inhibiting the binding of substance P to
Fig. 3 Change in plasma
substance P concentration
(n = 19). Top bar highest value
in the range of quartile 9 1.5;
lower bar lowest value in the
range of quartile 9 1.5; top of
box upper quartile; bottom of
box lower quartile; middle bar
median value; circles outliers
*P\0.05 between days 2 and 5
compared with baseline (day 1)
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123the NK1 receptor in the vomiting center [1], few studies
have been conducted to investigate the relationship
between the blood pharmacokinetics of substance P and
nausea/vomiting during treatment with chemotherapeutic
agents in humans. Substance P has been shown to be co-
localized with serotonin in enterochromafﬁn cells in the
gastrointestinal tract [16] and cross the blood–brain barrier
in animals [17]. These reports raise the possibility that
substance P of peripheral origin may act centrally to induce
emesis. However, it is still not shown whether exocytotic
release of substance P from enterochromafﬁn cells in the
gastrointestinal tract occurs after administration of emeto-
genic agents. This study showed that the plasma substance
P concentration signiﬁcantly increased on days 2–4 after
administration of chemotherapeutic agents. It was also
shown that the plasma substance P concentration signiﬁ-
cantly increased only in patients with delayed nausea/
vomiting. These results, as well as the report from Higa
[18], support the possibility that the elevation of the plasma
substance P concentration by emetogenic chemotherapeu-
tic agents may be involved in the pathogenesis of CINV,
especially in the delayed phase. The plasma substance P
concentration ranged from 0 to 1,608 pg/mL in a report by
Higa et al. [18] and from 2–55 pg/mL in the present study.
The cause of this difference is unknown, but may be
attributed to different assay kits used to measure the sub-
stance P concentration (Higa et al. used R&D systems, and
we used Cayman Chemical).
In conclusion, this study demonstrated similar plasma
pharmacokinetics of aprepitant in Japanese and non-Japa-
nese, the validity of reducing dexamethasone dose, and the
existence of increased substance P concentration in patients
receiving highly emetogenic cancer chemotherapy. Further
studies are required to clarify whether measurement of the
plasma pharmacokinetics of substance P may be a clini-
cally meaningful marker for CINV in patients receiving
emetogenic agents.
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